Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of bergenin in preparation of medicine for treating Klebsiella pneumoniae infection in vivo

A technology of Klebsiella and petrocyanin, applied in the direction of antibacterial drugs, drug combinations, antipyretics, etc., to achieve the effects of improving lung damage, reducing use, and reducing toxicity

Active Publication Date: 2020-03-10
CHINA AGRI UNIV +1
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] The purpose of the present invention is to enrich the medical use of petracenin and address the problem of insufficient treatment of Klebsiella pneumoniae in the prior art, and propose a kind of petracenin in the preparation of active drugs against Klebsiella pneumoniae new use of

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of bergenin in preparation of medicine for treating Klebsiella pneumoniae infection in vivo
  • Application of bergenin in preparation of medicine for treating Klebsiella pneumoniae infection in vivo
  • Application of bergenin in preparation of medicine for treating Klebsiella pneumoniae infection in vivo

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Effect of petracenin on cell viability

[0035] Experimental method:

[0036] The experiment was divided into 6 groups, namely the blank control group, the Klebsiella pneumoniae group, the low-dose begenin group, the middle-dose begenin group, the high-dose begenin group, and the dexamethasone group.

[0037] It is handled as follows:

[0038] RAW 264.7 cells were seeded into 96-well plates (2×10 6 cells / well) for 24 hours, then add low, medium and high doses of petracenin (1.5, 3, 6 μg / ml), and treat for 1 hour; and add dexamethasone (Dexamethasone, Dex) as a positive control (100 μg / ml), treatment time 1 hour; then the cells were exposed to the Klebsiella pneumoniae environment for 24 hours; the blank control group did not carry out any treatment; the Klebsiella pneumoniae group only carried out Klebsiella pneumoniae treatment , without adding other drugs.

[0039] Subsequently, the 96-well plate was washed twice with PBS, MTT (5 mg / ml) was added to the cells, and...

Embodiment 2

[0046] Effects of petracenin on antioxidant activity of cells

[0047] Experimental method:

[0048] The experiment was divided into 6 groups, namely: blank control group, Klebsiella pneumoniae group, low-dose petracenin group, middle-dose petracenin group, high-dose petracenin group, and dexamethasone group.

[0049] It is handled as follows:

[0050] 1. Inoculate RAW 264.7 cells into a 96-well plate (2×10 4 cells / well) for 24 hours, then add low, medium and high doses of petracenin (1.5, 3, 6 μg / ml) for 1 hour; and add dexamethasone (Dex) as a positive control (100 μg / ml), the treatment time was 1 hour; then the cells were exposed to the Klebsiella pneumoniae environment for 24 hours; the blank control group was not treated, and the Klebsiella pneumoniae group was only treated with Klebsiella pneumoniae without adding other medicines.

[0051] Afterwards, the cells were washed twice with ice-cold PBS, and stained with DCFH-DA for 20 min.

[0052] 2. Measure ROS generat...

Embodiment 3

[0060] Anti-inflammatory effect of petrinin on pneumonia mice infected by Klebsiella pneumoniae

[0061] The experiment was divided into 6 groups, namely: blank control group, Klebsiella pneumoniae group, low-dose petracenin group, middle-dose petracenin group, high-dose petracenin group, and dexamethasone group.

[0062] 1. Establishment and challenge of animal model

[0063] BALB / c male mice were divided into 6 groups: blank control group, Klebsiella pneumoniae group, dexamethasone group (100 μg / ml), petracenin low, middle and high dose groups (75, 150, 300 μg / kg), 15 in each group. Dexamethasone, low, medium and high doses of petracenin were injected subcutaneously into mice. One hour later, in addition to the blank control group, 10% chloral hydrate was injected intraperitoneally for anesthesia, and 30 μl of Klebsiella suspension (2×10 7 CFU), mice were dislocated 48 hours after infection. The blank control group did not do any operation, and the Klebsiella pneumoniae...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an application of bergenin in preparation of a medicine for treating Klebsiella pneumoniae in vivo, and belongs to the technical field of biology and medicines. The invention proves that the bergenin can improve the cell survival rate reduction caused by Klebsiella pneumoniae infection, the cell oxidative damage caused by Klebsiella pneumoniae infection is improved, inflammatory response caused by Klebsiella pneumoniae infection is improved, lung injury caused by Klebsiella pneumoniae infection is improved, Klebsiella pneumoniae infection of lung is reduced, phosphorylation of ERK, JNK and p38 is inhibited and phosphorylation of I kappa B and p65 is inhibited so that Klebsiella pneumoniae infection is treated. The application is beneficial to further development andutilization of bergenin.

Description

technical field [0001] The invention belongs to the technical field of biology and medicine, and in particular relates to the application of petracenin in the preparation of medicine for treating Klebsiella pneumoniae infection in vivo. Background technique [0002] Klebsiella pneumoniae is a Gram-negative bacterium that can rapidly adapt to the host environment, persist for long periods of time, and induce antimicrobial resistance. LPS, as a structural component of Gram-negative bacteria, is a major factor leading to lung injury and pneumonia, including alveolar epithelial cell permeability, inflammatory cytokine release, oxidative stress, etc. [0003] Currently, antibiotics are commonly used to treat pneumonia caused by Klebsiella pneumoniae. However, in recent years, the infection rate caused by Klebsiella pneumoniae has increased year by year, and the continuous increase of multi-drug resistant strains often leads to the failure of clinical antimicrobial therapy and th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/37A61P31/04A61P11/00A61P29/00A61P39/06
CPCA61K31/37A61P11/00A61P29/00A61P31/04A61P39/06
Inventor 郝智慧候冉冉李秋孙卓建王苹苹
Owner CHINA AGRI UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com